Trial Profile
A three month double-blind, randomized, placebo-controlled, parallel group, multi-center study with Creon 25.000 MMS in subjects after an attack of acute pancreatitis suffering from pancreatic exocrine insufficiency, followed by an open-label long-term extension of nine months.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 22 Jan 2015
Price :
$35
*
At a glance
- Drugs Pancreatin (Primary)
- Indications Exocrine pancreatic insufficiency
- Focus Therapeutic Use
- Sponsors Solvay
- 22 Jan 2015 New trial record